Lv31
268 积分 2023-05-27 加入
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1小时前
待确认
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
Bile acid metabolism in health and ageing-related diseases
1个月前
已完结
Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta-Analysis
1个月前
已完结
The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia
1个月前
已完结
Update on the management of HDV infection: current events and perspectives
1个月前
已完结
Hepatitis D Virus Infection
1个月前
已完结
The real life use of bulevirtide for treatment of chronic HDV infection: an interim analysis in the PITER cohort
1个月前
已完结
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers
2个月前
已完结
SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
2个月前
已完结
皖公网安备34019202002308
